BOC Sciences' Secukinumab monoclonal antibody.
Description
Secukinumab is a recombinant human IgG1κ monoclonal antibody that specifically binds to and inhibits interleukin (IL)-17A. Secukinumab was developed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis